loxicodegol (NKTR-181) - Nektar Therapeutics
Nektar Therapeutics: Investor and Analyst R&D Day (Nektar Therapeutics) - Oct 11, 2015 - “NKTR-181 Achieves Maximum Pupil Diameter Reduction Comparable to Oxycodone” 
P1 data • Pain
http://www.nektar.com/pdf/2015_Nektar_R&D_Day.pdf
 
Oct 11, 2015
 
.
 
cc1f544a-9417-4db5-a53b-cfa237a70f42.jpg